GENE ONLINE|News &
Opinion
Blog

2023-01-09| Trials & Approvals

Eisai and Biogen’s Alzheimer’s Med, Leqembi, Granted FDA Approval

by Reed Slater
Share To
On Saturday, the FDA announced it approved Eisai and Biogen’s jointly developed Alzheimer’s drug, Leqembi, under the accelerated approval program. The approval comes nearly two years after the regulatory agency approved the companies’ previous Alzheimer’s drug, Aduhelm, on the same accelerated pathway before it became the focal point of controversy in biotech. Alongside Leqembi’s accelerated approval, Eisai filed the drug’s supplemental Biologics License Application (sBLA) to gain traditional approval to provide wider access to the drug. 

It's free! Log in now to read

LATEST
Junshi’s PD-1 Antibody Meets Endpoint In Phase 3 Lung Cancer Trial
2023-01-19
Moderna Welcomes Phase 3 Win For RSV Vaccine
2023-01-18
Moving Beyond COVID With mRNA Technology
2023-01-18
Rob Knight and Jing-Yuan Fu Elaborate On Microbiome Research Trends at the 7th Asia Microbiome Conference(AMC)
2023-01-17
CARsgen Taps Huadong to Commercialize Multiple Myeloma CAR-T in China
2023-01-17
Scientists Study Imaging Probes in First-Ever Amputated Human Limb Model
2023-01-16
EMA Plans to Issue Liver Failure Warning for Novartis’ Gene Therapy
2023-01-16
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!